Status:
COMPLETED
Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy
Lead Sponsor:
Radboud University Medical Center
Conditions:
Peritoneal Carcinomatosis
Eligibility:
All Genders
18+ years
Brief Summary
Currently, there is a lack of knowledge on the effect of additional flushing after HIPEC on tumour platinum exposure, systemic platinum exposure and platinum concentration in drain exudate and thereby...
Detailed Description
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is standard care in the treatment of patients with peritoneal carcinomatosis as a result of intra-abdominal cancer...
Eligibility Criteria
Inclusion
- Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up.
- Note: Informed consent may be obtained prior to start of the specified screening window.
- Note: Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes.
- Age ≥ 18 years
- Confirmed diagnosis of preoperatively identifi ed primary or recurrent peritoneal carcinomatosis (PC) of colorectal origin who are planned for HIPEC treatment with oxaliplatin according to routine clinical care
Exclusion
- 1\) Patients who do not achieve a cytoreduction score of CC-0 will be excluded from the study.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03364907
Start Date
March 1 2018
End Date
December 30 2019
Last Update
October 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Netherlands